Publications by authors named "Rita Denbow"
Article Synopsis
- Predictive biomarkers like tumor SUVs on F-FDG PET/CT are crucial for determining responses to HER2-targeted therapies for ER-negative, HER2-positive breast cancer.
- The TBCRC026 trial showed that early declines in SUV can predict complete response rates and potential recurrence-free and overall survival outcomes after treatment with trastuzumab and pertuzumab without chemotherapy.
- Significant findings included that a C1D15 SUL of 3 or less was linked to improved recurrence-free survival and overall survival, while a decline of at least 40% in SUL wasn’t statistically significant for survival outcomes.
Current molecular liquid biopsy assays to detect recurrence or monitor response to treatment require sophisticated technology, highly trained personnel, and a turnaround time of weeks. We describe the development and technical validation of an automated Liquid Biopsy for Breast Cancer Methylation (LBx-BCM) prototype, a DNA methylation detection cartridge assay that is simple to perform and quantitatively detects nine methylated markers within 4.5 h.
View Article and Find Full Text PDF